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Major depression is a highly prevalent mood disorder (Kessler 
and Walters, 1998) associated with a significant social and eco-
nomic impact (Sheehan, 2002). However, the precise physio-
pathological mechanisms involved in the aetiology of this 
disorder and in the therapeutic actions of antidepressant (AD) 
drugs are still largely unknown (Berton and Nestler, 2006).
There is increasing evidence that the generation of new neurons 
and the dendritic reorganization of pre-existing neurons in the adult 
hippocampus are complementary neuroplastic phenomena involved 
not only in the onset of but also in the remission from depression 
(Mateus-Pinheiro et al., 2013; Snyder et al., 2011; Surget et al., 
2011). The potentiation of adult neurogenesis in the dentate gyrus 
of the hippocampus has been extensively described with the admin-
istration of different classes of AD drugs, namely with non-selec-
tive monoamine oxidase (MAO) inhibitors (Malberg et al., 2000), 
tricyclic antidepressants (TCAs) (Sairanen et al., 2005) and selec-
tive serotonin reuptake inhibitors (SSRIs) (Santarelli et al., 2003). 
These observations suggest that the different pharmacological inter-
ventions targeting monoaminergic neurotransmission have a com-
mon effect in adult neurogenesis. However, the effects of ADs in 
the reversal of stress-induced morphological changes of granule 
neurons in the hippocampus have only been described with TCAs 
and SSRIs (Bessa et al., 2009a; Jayatissa et al., 2006; Surget et al., 
2011). Thus, it remains to be established whether adult neurogene-
sis and dendritic reorganization of pre-existing hippocampal gran-
ule neurons after stress exposure are involved in the behavioural 
actions of selective reversible MAO-A inhibitors (RIMA).
In the present study, we evaluated the behavioural effects of the 
RIMA pirlindole (Macedo et al., 2011) and the SSRI fluoxetine in 
the chronic mild stress (CMS) animal model. In addition, we 
examined whether stress-induced changes in neurogenesis and 
neuronal plasticity within the hippocampus are influenced by these 
commonly used ADs. Our results demonstrate that, like fluoxetine, 
pirlindole is able to reverse the behavioural effects of stress expo-
sure while potentiating hippocampal adult neurogenesis and rescu-
ing the stress-induced dendritic atrophy of granule neurons.
Experimental procedures
Animals
Ninety-six male Wistar rats (Charles-River Laboratories, Barcelona, 
Spain), weight 300-400 g, age 2 months, were used in this study. 
Animals were housed (three per cage) under standard laboratory 
conditions (12 h light: 12 h dark cycle, lights on at 8 a.m., 22ºC, 
relative humidity 55%; free access to food and water). Animals 
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were assigned to one of the six treatment groups. A control group 
(n=16) and five treatment groups exposed to CMS: vehicle (n=16), 
fluoxetine 10 mg/kg (n=16), pirlindole 5 mg/kg (n=16), pirlindole 
15 mg/kg (n=16) and pirlindole 30 mg/kg (n=16). All procedures 
were carried out in accordance with the Portuguese national author-
ity for animal experimentation, Direção Geral de Veterinária (ID: 
DGV9457) and in accordance with the guidelines for the care and 
handling of laboratory animals in Directive 2010/63/EU of the 
European Parliament and Council.
Drugs
The drugs used were fluoxetine (10 mg/kg; Kemprotec, 
Middlesbrough, UK) and pirlindole (5, 15 and 30 mg/kg; Grupo 
Tecnimede, Sintra, Portugal). Compounds were dissolved in ster-
ile distilled water with sonication and administered intraperito-
neally (1 mL/kg) to animals, daily at 20:00. During the last 3 
weeks of CMS, animals were given daily injections with vehicle 
(n=16), fluoxetine 10 mg/kg (n=16), pirlindole 5 mg/kg (n=16), 
pirlindole 15 mg/kg (n=16) and pirlindole 30 mg/kg (n=16). The 
daily doses of AD drugs administered chosen were based on their 
therapeutic effects as described in the literature (Bruhwyler et al., 
1997; Song et al., 2006).
Chronic mild stress
A slightly modified version of an unpredictable CMS protocol 
was used (Bessa et al., 2009b; Willner, 2005). It consisted of 
chronic exposure to unpredictable mild stressors (confinement in 
a restricted space for 1 h, placement in a tilted cage [30º] for 4 h, 
housing on damp bedding for 8 h, overnight illumination, food 
deprivation for 18 h followed by exposure to inaccessible food 
for 1 h, water deprivation for 18 h followed by exposure to an 
empty bottle for 1 h, overcrowding for 4 h, exposure to noise for 
4 h, exposure to strobe lights for 4 h and reversed light/dark cycle 
for 48 h every 7 days) over 7 weeks (Supplementary Table 1).
Sucrose preference test
Anhedonia was assessed weekly during exposure to CMS using 
the sucrose preference test (SPT). Briefly, animals were allowed to 
habituate to the sucrose solution in three baseline trials of 1 h expo-
sure to 1% sucrose solution or tap water, following 18 h of food 
and water deprivation 1 week before the CMS protocol, to estab-
lish baseline preference levels. To test sucrose preference, animals 
that were food- and water-deprived for 18 h (Supplementary Table 
1) were presented with two pre-weighed bottles containing 1% 
sucrose solution or tap water for a period of 1 h. Sucrose prefer-
ence was calculated according to the formula: sucrose preference = 
[sucrose intake / (sucrose intake + water intake)] X 100, as previ-
ously described (Bekris et al., 2005).
Forced swimming test
Depressive-like behaviour was evaluated in the forced swimming 
test (FST) on the last day of exposure to CMS. Twenty-four hours 
after a pre-test session (10 min), rats were placed in transparent 
glass cylinders (64 cm height and 22 cm diameter) filled with 
water (25ºC; depth 30 cm) for a period of 5 min. Test sessions 
were assessed using a camera connected to a video tracking sys-
tem (Viewpoint, Lyon, France); the system automatically calcu-
lated immobility time and latency to immobility. Depressive-like 
behaviour was defined as an increase in time of immobility and a 
decrease in latency to immobility (Castagné et al., 2011).
Immunostaining procedures
For cell proliferation and cell phenotype analysis, eight animals 
from each experimental group were injected with a single dose of 
BrdU (100 mg/kg, Sigma-Aldrich, St Louis, USA) 24 h before sac-
rifice (Landgren and Curtis, 2011). At the end of the experimental 
procedures, animals were sacrificed under anaesthesia. Serial coro-
nal sections (20 μm) were cut and stained for BrdU (1:50; Dako, 
Glostrup, Denmark). Sections were then double-stained with PSA-
NCAM for neuroblasts (1:500; Millipore, Billerica, MA, USA) or 
GFAP for glial cells (1:200; Dako). Proliferation densities were 
estimated in the subgranular zone (SGZ) of the dentate gyrus as a 
ratio between the total number of immunostained cells and the area 
of the SGZ, using an Olympus BX51 optical microscope and 
Newcast software (Visiopharm, Hoersholm, Denmark). For each 
animal, eight sections were analysed. The double staining with neu-
ronal (PSA-NCAM) or glial (GFAP) markers (von Bohlen, 2011) 
were performed using a confocal microscope (Olympus FV1000) 
and an optical microscope (Olympus BX51), respectively.
Structural analysis
For the 3D morphometric analysis, six animals from each treat-
ment group were transcardially perfused with 0.9% saline and 
processed (Gibb and Kolb, 1998). Briefly, brains were immersed 
in Golgi-Cox solution for 21 days (Glaser and Van der Loos, 
1981), transferred to a 30% sucrose solution and cut on a 
vibratome. Coronal sections (200 μm thick) were collected in 6% 
sucrose and blotted dry onto gelatin-coated microscope slides. 
They were subsequently alkalinised in 18.7% ammonia, devel-
oped in Dektol (Kodak), fixed in Kodak Rapid Fix, dehydrated 
and xylene-cleared before coverslipping. Dendritic arborisation 
and spine numbers and shape of granule neurons were analysed 
using a motorized microscope (Axioplan 2, Carl Zeiss) and 
Neurolucida software (Microbrightfield, Willinston, USA). A 3D 
analysis of the reconstructed neurons was performed using 
NeuroExplorer software (MicroBrightfield, Inc.). Forty neurons 
were studied for each animal and measurements from individual 
neurons were averaged for each animal. Several aspects of den-
dritic morphology were examined, namely, the total dendritic 
length, dendritic spine density, spine morphology and Sholl anal-
ysis to evaluate the spatial arrangement of dendritic material by 
quantifying the number of dendritic intersections at concentric 
20-μm intervals from the soma (Harris et al., 1992).
Statistical analysis
After confirmation of homogeneity, appropriate statistical tests 
were applied to the data. Repeated measures ANOVA was used to 
analyse the results of the sucrose consumption test. One-way 
ANOVA was used to evaluate the impact of stress and the effect 
of ADs in further behavioural and structural data. Differences 
between groups were then determined by Tukey’s honestly 
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significant difference test (Tukey HSD) post-hoc analysis. 
Statistical significance was accepted for P<0.05. Results are 
expressed as mean + s.e.m.
Results
Behavioural results
The analysis of the SPT during the first 4 weeks of the CMS 
protocol revealed a significant decrease of sucrose preference in 
animals exposed to chronic stress treated with vehicle 
(F1,94=9.147; P=0.003) confirming the induction of an anhedonic 
behavioural phenotype. During the last 3 weeks of the CMS pro-
tocol, a significant global effect of treatment was observed 
(F5,90=5.964; P<0.001). Post-hoc analysis revealed significant 
differences between the animals treated with vehicle and animals 
treated with pirlindole 5 mg/kg (P=0.001). However, no signifi-
cant differences were observed with fluoxetine or with higher 
doses of pirlindole (Figure 1a). Concerning behaviour in the FST, 
a significant increase in immobility time (F1,32=23.839; P<0.001) 
and decrease in latency to immobility time (F1,32=23.834; 
P<0.001) was observed in stress-exposed animals (Figure 1b,c). 
AD treatment proved to be a significant factor in recovery from 
depressive-like behaviour in the FST (F4,80=7.433; P<0.001). 
Fluoxetine reversed the stress-induced behaviour in immobility 
time (P=0.012) and in latency to immobility time (P<0.001). 
Similarly, treatment with pirlindole induced a significant decrease 
in immobility time at dosages of 5 mg/kg (P<0.001) and 15 mg/
kg (P<0.001) and an increase in latency to immobility time at 
dosages of 5 mg/kg (P=0.043) and 15 mg/kg (P<0.001). No sig-
nificant effects were observed at a dosage of pirlindole 30 mg/kg.
Cell proliferation, neurogenesis and 
glial phenotype
Cell proliferation analysis (Figure 2a,b) revealed a non-significant 
decrease in the density of BrdU-positive cells in animals exposed to 
CMS (F1,16=2.090; P=1.170). However, an overall effect of AD 
treatment was observed (F4,40=2.697; P=0.046) with a significant 
increase associated with fluoxetine treatment (P=0.029) in com-
parison with vehicle-treated animals. Adult neurogenesis assessed 
by co-labelling of BrdU with neuroblast marker PSA-NCAM 
(Figure 2c,d) was significantly decreased with stress exposure 
(F1,16=6.728; P=0.021). A significant effect of AD treatment was 
observed (F4,40=5.235; P=0.002). Both fluoxetine (P=0.033) and 
pirlindole at all dosages tested (5 mg/kg, P=0.035; 15 mg/kg, 
P=0.005; 30 mg/kg, P=0.005), increased adult neurogenesis in the 
SGZ. No significant effects of stress exposure or AD treatment 
were observed in glial lineage in the SGZ as assessed by co-label-
ling of BrdU with glial cell marker GFAP (Figure 2e,f).
Structural analysis
The three-dimensional morphometric analysis of Golgi-
impregnated neurons in the dentate gyrus (Figure 3) revealed that 
Figure 1. Behavioural effects of fluoxetine and pirlindole on hedonic and depressive-like behaviour. (a) Sucrose preference in the SPTs performed 
during CMS. #P=0.003, *P<0.001. (b) Immobility time and (c) latency to immobility time in the forced swimming test performed after CMS and drug 
administration. #P<0.001, *P<0.05; **P<0.05, ***P< 0.001. Data presented as mean + s.e.m.
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exposure to CMS induced atrophy in granule neurons, with a sig-
nificant decrease in their total dendritic length (F1,12=11.358; 
P=0.007). Importantly, this atrophic effect of chronic stress was 
reversed after administration of ADs (F4,30=5.422; P=0.003). 
Both fluoxetine (P=0.002) and pirlindole at dosages of 30 mg/kg 
(P=0.040) significantly increased total dendritic length. No sig-
nificant effects of stress exposure or antidepressant treatment 
were observed in spine densities, spine morphology or Sholl 
analysis (Supplementary Figure 1).
Discussion
The results of this study reveal that the RIMA pirlindole is able to 
reverse stress-induced anhedonia and confirm the previously 
described AD effects of pirlindole in the FST (Bruhwyler et al., 
1998). This concordance between the reversal of anhedonic 
behaviour in the SPT and the decrease in immobility in the FST, 
similar to the one observed with the SSRI fluoxetine, confirms 
the AD effects of pirlindole in this validated animal model of 
Figure 2. Cell proliferation, neurogenesis and glial phenotype. (a) Proliferative niche of BrdU-labelled cells in the subgranular zone (SGZ) obtained 
with optical microscopy. (b) The density of BrdU-labelled cells in the SGZ of the dentate gyrus. *P<0.05. (c) Niche of newly formed neurons in the 
SGZ, obtained by confocal microscopy. Green: BrdU-positive cells; red: PSA-NCAM-positive cells. (d) The percentage of BrdU-immunopositive cells 
that were co-labelled with antibodies against PSA-NCAM in the SGZ. #P<0.05, *P<0.05; **P<0.05, ***P=0.005, ****P=0.005. (e) Newly formed glial 
cells in the SGZ, obtained by optical microscopy. Green: GFAP-positive cell; red: BrdU-positive cell. (f) Percentage of BrdU-positive cells that were 
co-labelled with glial marker GFAP in the SGZ. Data represented as mean + s.e.m.
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depression (Bessa et al., 2009b). However, the fact that sucrose 
preference was evaluated after food deprivation does not exclude 
the possibility that metabolic demands may be involved in these 
behavioural results in the SPT. Importantly, the treatment with 
fluoxetine and pirlindole effectively restored the generation of 
new neurons in the SGZ without affecting glial cells and reversed 
the atrophic changes induced by chronic stress.
Interestingly, the results suggest that the effects of pirlindole on 
depressive-like behaviour are dose-dependent, with the lower dos-
ages showing the ability to reverse the stress-induced changes in the 
sucrose preference and forced swimming test. However, the effects 
of this drug in the modulation of hippocampal adult neurogenesis 
are present at all the doses used. This observation is in accordance 
with the notion that the mood-improving effects of antidepressants 
are not exclusively dependent on the ability to modulate the genera-
tion of new hippocampal neurons (Bessa et al., 2009a).
The observation that the impact of CMS and ADs was sig-
nificant on hippocampal neurogenesis but not on cell prolifera-
tion suggests that these processes may be differently regulated. 
This is in accordance with previous studies regarding the 
effects of CMS and ADs on the proliferation, differentiation 
and survival of newly born hippocampal cells (Lee et al., 2006; 
Mateus-Pinheiro et al., 2013). Furthermore, the fact that the 
highest dose of pirlindole failed to reveal significant AD effects 
while reversing the effects of stress on dendritic length, sug-
gests a possible dissociation between the behavioural and neu-
roplastic effects of this drug.
In conclusion, this study provides the first demonstration that 
MAO-A selective inhibition reverses the deleterious neuroplastic 
effects of chronic stress in the hippocampus by restoring adult 
neurogenesis and by rescuing dendritic atrophy of granule neu-
rons. Taking into account the fact that the subtype A of MAO pref-
erentially metabolizes serotonin and noradrenaline (Syha and 
Schraven, 1990), these results further reinforce the notion that the 
modulation of monoaminergic neurotransmission is a critical fac-
tor for the neuroplastic effects of currently available antidepres-
sant drugs.
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